These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 30591287)

  • 1. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population.
    Huber CA; Meyer MR; Steffel J; Blozik E; Reich O; Rosemann T
    Clin Ther; 2019 Jan; 41(1):107-117. PubMed ID: 30591287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
    Di Martino M; Alagna M; Lallo A; Gilmore KJ; Francesconi P; Profili F; Scondotto S; Fantaci G; Trifirò G; Isgrò V; Davoli M; Fusco D
    BMC Cardiovasc Disord; 2021 Apr; 21(1):180. PubMed ID: 33853534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality.
    Mathews R; Wang W; Kaltenbach LA; Thomas L; Shah RU; Ali M; Peterson ED; Wang TY
    Circulation; 2018 May; 137(20):2128-2138. PubMed ID: 29386204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes.
    Bansilal S; Castellano JM; Garrido E; Wei HG; Freeman A; Spettell C; Garcia-Alonso F; Lizano I; Arnold RJ; Rajda J; Steinberg G; Fuster V
    J Am Coll Cardiol; 2016 Aug; 68(8):789-801. PubMed ID: 27539170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarction.
    Di Martino M; Kirchmayer U; Agabiti N; Bauleo L; Fusco D; Perucci CA; Davoli M
    BMJ Open; 2015 Jun; 5(6):e007866. PubMed ID: 26063569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
    Soldati S; Di Martino M; Rosa AC; Fusco D; Davoli M; Mureddu GF
    BMC Cardiovasc Disord; 2021 Sep; 21(1):466. PubMed ID: 34565326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Adherence and Long-Term Outcomes in Non-Revascularized Patients Following Acute Myocardial Infarction.
    Khan R; Kaul P; Islam S; Savu A; Bagai A; van Diepen S; Bainey KR; Welsh RC; Goodman SG
    Am J Cardiol; 2021 Aug; 152():49-56. PubMed ID: 34120704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U; Kirchberger I; Heier M; Thilo C; Kuch B; Meisinger C
    Eur J Intern Med; 2018 Jan; 47():62-68. PubMed ID: 28826823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC; Peterson ED; Kaltenbach LA; Cannon CP; Choudhry NK; Henry TD; Anstrom KJ; Cohen DJ; Fonseca E; Khan ND; Fonarow GC; Wang TY
    JAMA Cardiol; 2020 Jan; 5(1):38-46. PubMed ID: 31721978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
    Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
    J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Organisational determinants of adherence to secondary prevention medications after acute myocardial infarction].
    Perrone E; Lenzi J; Avaldi VM; Castaldini I; Protonotari A; Rucci P; Piccinni C; Morini M; Fantini MP
    Epidemiol Prev; 2015; 39(2):106-14. PubMed ID: 26036739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis.
    Setoguchi S; Glynn RJ; Avorn J; Mittleman MA; Levin R; Winkelmayer WC
    J Am Coll Cardiol; 2008 Apr; 51(13):1247-54. PubMed ID: 18371553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term medication adherence after myocardial infarction: experience of a community.
    Shah ND; Dunlay SM; Ting HH; Montori VM; Thomas RJ; Wagie AE; Roger VL
    Am J Med; 2009 Oct; 122(10):961.e7-13. PubMed ID: 19560749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction.
    Faridi KF; Peterson ED; McCoy LA; Thomas L; Enriquez J; Wang TY
    JAMA Cardiol; 2016 May; 1(2):147-55. PubMed ID: 27437885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.
    Margulis AV; Choudhry NK; Dormuth CR; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1088-97. PubMed ID: 21538672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
    Choudhry NK; Setoguchi S; Levin R; Winkelmayer WC; Shrank WH
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1189-96. PubMed ID: 18956426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction.
    Adamek KE; Ramadurai D; Gunzburger E; Plomondon ME; Ho PM; Raghavan S
    J Am Heart Assoc; 2019 Feb; 8(3):e011448. PubMed ID: 30712488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.